News
You've been feeling fatigued and have gained some weight. It could be just a sign that you're getting older, but there might ...
Global pharmaceutical firm Merck has launched ThyroAfrica in Kenya, a continent-wide awareness campaign targeting the rising burden of thyroid disorders in Africa.
Everyone faces unique obstacles when it comes to weight loss. Some roadblocks stem from past experiences with weight ...
15h
MedPage Today on MSNNew PD-1 Inhibitor Approved for Nasopharyngeal CarcinomaThe FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...
Thyroid disorders impact over 42 million Indians, affecting energy, mood, and metabolism. Early diagnosis, proper diet, and routine monitoring are vital for effective management and prevention., Healt ...
For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...
Q: My husband had been getting testosterone shots every three weeks for many years for Low T. I was concerned that this might be affecting his heart, so he agreed to stop the shots this summer and see ...
18h
Real Simple on MSNWhat Nutrition Experts Really Think About the ‘Dinosaur Time’ Spinach Trend That's Taking Over TikTokThis food hack has been popularized on TikTok by creator @sahmthingsup, who eats handfuls of greens such as spinach during ...
On April 23, 2025, the U.S. Food and Drug Administration (FDA) granted approval to Akeso Biopharma Co., Ltd.’s penpulimab-kcqx for the first-line treatment of adults with recurrent or metastatic ...
During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...
Hormonal imbalance is a key trigger of hair fall. Traya tackles this via a personalised plan combining dermatology, Ayurveda, ...
Will Bulsiewicz, M.D. is a respected gastroenterologist who wrote “Fiber Fueled.” Today’s column is based on this book. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results